[
    [
        {
            "time": "",
            "original_text": "[买入评级]泰格医药(300347)年报点评：BE试验+创新药临床 公司业绩持续高速增长",
            "features": {
                "keywords": [
                    "泰格医药",
                    "BE试验",
                    "创新药",
                    "临床",
                    "业绩",
                    "高速增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级]泰格医药(300347)年报点评：BE试验+创新药临床 公司业绩持续高速增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[买入-A评级]泰格医药(300347)年报点评：CRO行业高景气 收入和净利润高速增长",
            "features": {
                "keywords": [
                    "泰格医药",
                    "CRO行业",
                    "高景气",
                    "收入",
                    "净利润",
                    "高速增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入-A评级]泰格医药(300347)年报点评：CRO行业高景气 收入和净利润高速增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级]泰格医药(300347)年报点评：业绩符合预期 受益创新药发展趋势",
            "features": {
                "keywords": [
                    "泰格医药",
                    "业绩",
                    "符合预期",
                    "创新药",
                    "发展趋势"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级]泰格医药(300347)年报点评：业绩符合预期 受益创新药发展趋势",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]